{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/RLAY/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-19T13:08:19.320Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":7036,"canonical_name":"Relay Therapeutics, Inc.","cik":"0001812364","uei":null,"lei":null,"duns":null,"ticker":"RLAY"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":66,"clinical":3},"count":69,"timeline":[{"ts":"2026-10-08","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-10-08","url_slug":"/sec/cik-0001812364/4/0001193125-26-418094","accession_number":"0001193125-26-418094","importance":30},{"ts":"2026-10-08","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-10-08","url_slug":"/sec/cik-0001812364/4/0001193125-26-418096","accession_number":"0001193125-26-418096","importance":30},{"ts":"2026-10-07","kind":"sec.filing","form_type":"144","title":"144 — Relay Therapeutics, Inc. — 2026-10-07","url_slug":"/sec/cik-0001812364/144/0001950047-26-010107","accession_number":"0001950047-26-010107","importance":30},{"ts":"2026-10-06","kind":"sec.filing","form_type":"144","title":"144 — Relay Therapeutics, Inc. — 2026-10-06","url_slug":"/sec/cik-0001812364/144/0001950047-26-010071","accession_number":"0001950047-26-010071","importance":30},{"ts":"2026-09-09","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-09-09","url_slug":"/sec/cik-0001812364/4/0001193125-26-386455","accession_number":"0001193125-26-386455","importance":30},{"ts":"2026-09-09","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-09-09","url_slug":"/sec/cik-0001812364/4/0001193125-26-386464","accession_number":"0001193125-26-386464","importance":30},{"ts":"2026-08-28","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-08-28","url_slug":"/sec/cik-0001812364/4/0001193125-26-374645","accession_number":"0001193125-26-374645","importance":30},{"ts":"2026-08-26","kind":"sec.filing","form_type":"144","title":"144 — Relay Therapeutics, Inc. — 2026-08-26","url_slug":"/sec/cik-0001812364/144/0001950047-26-008711","accession_number":"0001950047-26-008711","importance":30},{"ts":"2026-08-25","kind":"sec.filing","form_type":"144","title":"144 — Relay Therapeutics, Inc. — 2026-08-25","url_slug":"/sec/cik-0001812364/144/0001493152-26-040137","accession_number":"0001493152-26-040137","importance":30},{"ts":"2026-08-18","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-08-18","url_slug":"/sec/cik-0001812364/4/0001193125-26-355493","accession_number":"0001193125-26-355493","importance":30},{"ts":"2026-08-18","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-08-18","url_slug":"/sec/cik-0001812364/4/0001193125-26-355502","accession_number":"0001193125-26-355502","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Relay Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001812364/schedule-13g-a/0001831942-26-000036","accession_number":"0001831942-26-000036","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Relay Therapeutics, Inc. — 2026-08-07","url_slug":"/sec/cik-0001812364/schedule-13g-a/0000315066-26-002255","accession_number":"0000315066-26-002255","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Relay Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0001812364/schedule-13g/0000315066-26-002113","accession_number":"0000315066-26-002113","importance":55},{"ts":"2026-08-06","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Relay Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0001812364/10-q/0001193125-26-338056","accession_number":"0001193125-26-338056","importance":45},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Relay Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0001812364/8-k/0001193125-26-338013","accession_number":"0001193125-26-338013","importance":35},{"ts":"2026-08-06","kind":"sec.filing","form_type":"424B5","title":"424B5 — Relay Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0001812364/424b5/0001193125-26-338292","accession_number":"0001193125-26-338292","importance":30},{"ts":"2026-08-04","kind":"sec.filing","form_type":"144","title":"144 — Relay Therapeutics, Inc. — 2026-08-04","url_slug":"/sec/cik-0001812364/144/0001950047-26-007601","accession_number":"0001950047-26-007601","importance":30},{"ts":"2026-07-31","kind":"sec.filing","form_type":"144","title":"144 — Relay Therapeutics, Inc. — 2026-07-31","url_slug":"/sec/cik-0001812364/144/0001950047-26-007457","accession_number":"0001950047-26-007457","importance":30},{"ts":"2026-07-30","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-07-30","url_slug":"/sec/cik-0001812364/4/0001193125-26-326142","accession_number":"0001193125-26-326142","importance":30},{"ts":"2026-07-30","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-07-30","url_slug":"/sec/cik-0001812364/4/0001193125-26-326144","accession_number":"0001193125-26-326144","importance":30},{"ts":"2026-07-28","kind":"sec.insider.s","reporter":"Bergstrom Donald A","title":"President, R&D","shares":2237,"price_per_share":18.61,"usd_value":41631,"security_title":"Common Stock","importance":35.04163057},{"ts":"2026-07-28","kind":"sec.insider.s","reporter":"Catinazzo Thomas","title":"Chief Financial Officer","shares":1459,"price_per_share":18.61,"usd_value":27152,"security_title":"Common Stock","importance":35.02715199},{"ts":"2026-07-28","kind":"sec.insider.s","reporter":"Rahmer Peter","title":"See remarks","shares":748,"price_per_share":18.61,"usd_value":13920,"security_title":"Common Stock","importance":35.01392028},{"ts":"2026-07-21","kind":"sec.form144","reporter":"SEKAR KATHIRESAN","title":"Director","shares":30000,"usd_value":594414,"security_title":"Common","approx_sale_date":"2026-07-21","accession_number":"0001950047-26-007243","importance":40.1188828},{"ts":"2026-07-21","kind":"sec.filing","form_type":"144","title":"144 — Relay Therapeutics, Inc. — 2026-07-21","url_slug":"/sec/cik-0001812364/144/0001950047-26-007243","accession_number":"0001950047-26-007243","importance":30},{"ts":"2026-07-20","kind":"sec.form144","reporter":"SEKAR KATHIRESAN","title":"Director","shares":66055,"usd_value":1293555,"security_title":"Common","approx_sale_date":"2026-07-20","accession_number":"0001950047-26-007212","importance":40.258711014},{"ts":"2026-07-20","kind":"sec.filing","form_type":"144","title":"144 — Relay Therapeutics, Inc. — 2026-07-20","url_slug":"/sec/cik-0001812364/144/0001950047-26-007212","accession_number":"0001950047-26-007212","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-07-08","url_slug":"/sec/cik-0001812364/4/0001193125-26-298679","accession_number":"0001193125-26-298679","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-07-08","url_slug":"/sec/cik-0001812364/4/0001193125-26-298681","accession_number":"0001193125-26-298681","importance":30},{"ts":"2026-07-07","kind":"sec.form144","reporter":"SANJIV PATEL","title":"Director, Officer","shares":144597,"usd_value":2732883,"security_title":"Common","approx_sale_date":"2026-07-07","accession_number":"0001950047-26-006935","importance":40.54657666},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Patel Sanjiv","title":"President and CEO","shares":48199,"price_per_share":19.58,"usd_value":943736,"security_title":"Common Stock","importance":35.94373642},{"ts":"2026-07-07","kind":"sec.filing","form_type":"144","title":"144 — Relay Therapeutics, Inc. — 2026-07-07","url_slug":"/sec/cik-0001812364/144/0001950047-26-006935","accession_number":"0001950047-26-006935","importance":30},{"ts":"2026-07-06","kind":"sec.insider.s","reporter":"Catinazzo Thomas","title":"Chief Financial Officer","shares":17717,"price_per_share":18.69,"usd_value":331131,"security_title":"Common Stock","importance":35.33113073},{"ts":"2026-07-06","kind":"sec.insider.s","reporter":"Bergstrom Donald A","title":"President, R&D","shares":8660,"price_per_share":18.71,"usd_value":162029,"security_title":"Common Stock","importance":35.1620286},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001812364/4/0001193125-26-294528","accession_number":"0001193125-26-294528","importance":30},{"ts":"2026-06-30","kind":"sec.form144","reporter":"PETER RAHMER","title":"Officer","shares":50000,"usd_value":987000,"security_title":"Common","approx_sale_date":"2026-06-30","accession_number":"0001950047-26-006653","importance":40.1974},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Rahmer Peter","title":"See remarks","shares":50000,"price_per_share":19.09,"usd_value":954500,"security_title":"Common Stock","importance":35.9545},{"ts":"2026-06-30","kind":"sec.filing","form_type":"144","title":"144 — Relay Therapeutics, Inc. — 2026-06-30","url_slug":"/sec/cik-0001812364/144/0001950047-26-006653","accession_number":"0001950047-26-006653","importance":30},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Rahmer Peter","title":"See remarks","shares":3056,"price_per_share":6.95,"usd_value":21239,"security_title":"Common Stock","importance":15.0212392},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Patel Sanjiv","title":"President and CEO","shares":3056,"price_per_share":6.95,"usd_value":21239,"security_title":"Common Stock","importance":15.0212392},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — Catinazzo Thomas — 2026-06-24","url_slug":"/sec/cik-0001818261/4/0001193125-26-281061","accession_number":"0001193125-26-281061","importance":30},{"ts":"2026-06-22","kind":"sec.form144","reporter":"THOMAS CATINAZZO","title":"Officer","shares":204880,"usd_value":3253494,"security_title":"Common","approx_sale_date":"2026-06-22","accession_number":"0001950047-26-006398","importance":40.65069888},{"ts":"2026-06-22","kind":"sec.form144","reporter":"DONALD BERGSTROM","title":"Officer","shares":110646,"usd_value":1757058,"security_title":"Common","approx_sale_date":"2026-06-22","accession_number":"0001950047-26-006399","importance":40.351411696},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"Bergstrom Donald A","title":"President, R&D","shares":93456,"price_per_share":16.94,"usd_value":1583145,"security_title":"Common Stock","importance":36.58314464},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"Catinazzo Thomas","title":"Chief Financial Officer","shares":61563,"price_per_share":16.97,"usd_value":1044724,"security_title":"Common Stock","importance":36.04472411},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"Catinazzo Thomas","title":"Chief Financial Officer","shares":56323,"price_per_share":16.97,"usd_value":955801,"security_title":"Common Stock","importance":35.95580131},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"Catinazzo Thomas","title":"Chief Financial Officer","shares":51560,"price_per_share":16.97,"usd_value":874973,"security_title":"Common Stock","importance":35.8749732},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"Catinazzo Thomas","title":"Chief Financial Officer","shares":17717,"price_per_share":17.01,"usd_value":301366,"security_title":"Common Stock","importance":35.30136617},{"ts":"2026-06-22","kind":"sec.filing","form_type":"144","title":"144 — Relay Therapeutics, Inc. — 2026-06-22","url_slug":"/sec/cik-0001812364/144/0001950047-26-006398","accession_number":"0001950047-26-006398","importance":30},{"ts":"2026-06-22","kind":"sec.insider.m","reporter":"Bergstrom Donald A","title":"President, R&D","shares":93456,"price_per_share":4.12,"usd_value":385039,"security_title":"Common Stock","importance":15.38503872},{"ts":"2026-06-22","kind":"sec.insider.m","reporter":"Catinazzo Thomas","title":"Chief Financial Officer","shares":61563,"price_per_share":5.22,"usd_value":321359,"security_title":"Common Stock","importance":15.32135886},{"ts":"2026-06-22","kind":"sec.insider.m","reporter":"Catinazzo Thomas","title":"Chief Financial Officer","shares":56323,"price_per_share":5.04,"usd_value":283868,"security_title":"Common Stock","importance":15.28386792},{"ts":"2026-06-22","kind":"sec.insider.m","reporter":"Catinazzo Thomas","title":"Chief Financial Officer","shares":51560,"price_per_share":4.45,"usd_value":229442,"security_title":"Common Stock","importance":15.229442},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001812364/4/0001193125-26-265904","accession_number":"0001193125-26-265904","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001812364/4/0001193125-26-265913","accession_number":"0001193125-26-265913","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"8-K","title":"8-K — Relay Therapeutics, Inc. — 2026-06-09","url_slug":"/sec/cik-0001812364/8-k/0001193125-26-263873","accession_number":"0001193125-26-263873","importance":35},{"ts":"2026-05-21","kind":"sec.filing","form_type":"8-K","title":"8-K — Relay Therapeutics, Inc. — 2026-05-21","url_slug":"/sec/cik-0001812364/8-k/0001193125-26-234862","accession_number":"0001193125-26-234862","importance":35},{"ts":"2026-05-21","kind":"sec.filing","form_type":"424B5","title":"424B5 — Relay Therapeutics, Inc. — 2026-05-21","url_slug":"/sec/cik-0001812364/424b5/0001193125-26-234428","accession_number":"0001193125-26-234428","importance":30},{"ts":"2026-05-19","kind":"sec.filing","form_type":"8-K","title":"8-K — Relay Therapeutics, Inc. — 2026-05-19","url_slug":"/sec/cik-0001812364/8-k/0001193125-26-229770","accession_number":"0001193125-26-229770","importance":35},{"ts":"2026-05-19","kind":"sec.filing","form_type":"424B5","title":"424B5 — Relay Therapeutics, Inc. — 2026-05-19","url_slug":"/sec/cik-0001812364/424b5/0001193125-26-231113","accession_number":"0001193125-26-231113","importance":30},{"ts":"2026-05-14","kind":"sec.form144","reporter":"THOMAS CATINAZZO","title":"Officer","shares":37234,"usd_value":492233,"security_title":"Common","approx_sale_date":"2026-05-14","accession_number":"0001950047-26-004516","importance":40.098446696},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Catinazzo Thomas","title":"Chief Financial Officer","shares":17717,"price_per_share":12.86,"usd_value":227841,"security_title":"Common Stock","importance":35.22784062},{"ts":"2026-05-14","kind":"sec.filing","form_type":"144","title":"144 — Relay Therapeutics, Inc. — 2026-05-14","url_slug":"/sec/cik-0001812364/144/0001950047-26-004516","accession_number":"0001950047-26-004516","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"4","title":"4 — Relay Therapeutics, Inc. — 2026-05-14","url_slug":"/sec/cik-0001812364/4/0001193125-26-224545","accession_number":"0001193125-26-224545","importance":30},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"Relay Therapeutics, Inc.","title":"A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07584226","excerpt":"[\"NRAS Mutation\",\"NRAS-mutant Advanced Melanoma\",\"NRAS-mutant Solid Tumors\",\"NRAS Q61R\",\"NRAS Q61K\",\"NRAS Q61L\",\"NRAS Q61H\",\"NRAS G12D\",\"NRAS G13R\",\"NRAS G13D\",\"NRAS G12V\"]","importance":30},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Relay Therapeutics, Inc.","title":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06982521","excerpt":"[\"PIK3CA Mutation\",\"HER2- Negative Breast Cancer\",\"Hormone Receptor Positive Tumor\",\"Breast Cancer\",\"Metastatic Breast Cancer\",\"Advanced Breast Cancer\"]","importance":60},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Relay Therapeutics, Inc.","title":"A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06789913","excerpt":"[\"PIK3CA-Related Overgrowth Spectrum (PROS)\",\"Lymphatic Malformations\",\"Vascular Malformations\",\"PIK3CA Mutation\",\"CLOVES Syndrome\",\"Klippel Trenaunay Syndrome\",\"Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)\"]","importance":45},{"ts":"2026-04-27","kind":"sec.filing","form_type":"8-K","title":"8-K — Relay Therapeutics, Inc. — 2026-04-27","url_slug":"/sec/cik-0001812364/8-k/0001193125-26-179404","accession_number":"0001193125-26-179404","importance":35}]}